North America preventive vaccines market is expected to grow by 10.42% annually in the forecast period and reach $30.02 billion by 2026 owing to increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 51 tables and 48 figures, this 131-page report “North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please
ALSO READ : http://www.marketwatch.com/story/june-2021-report-on-globa-north-am...
note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
ALSO READ : http://www.marketwatch.com/story/global-aluminum-magnesium-alloy-wi...
Based on Disease, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
ALSO READ : http://www.marketwatch.com/story/global-automatic-car-washer-market...
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
ALSO READ : http://www.marketwatch.com/story/global-baby-mats-and-gyms-industry...
Table of Contents
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter’s Fiver Forces Analysis 35
3 Segmentation of North America Market by Vaccine Type 39
3.1 Market Overview by Vaccine Type 39
3.2 Live/Attenuated Vaccines 41
3.3 Inactivated Vaccines 42
3.4 Subunit Vaccines 43
3.5 Toxoid Vaccines 44
3.6 Conjugate Vaccines 45
3.7 Recombinant Vector Vaccines 46
3.8 Other Vaccines 47
4 Segmentation of North America Market by Disease 48
4.1 Market Overview by Disease 48
4.2 Vaccines for Pneumococcal Disease 50
4.3 Vaccines for Poliovirus 51
4.4 Vaccines for Hepatitis 52
4.5 Vaccines for Influenza 53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54
4.7 Vaccines for Varicella 55
4.8 Vaccines for Human Papilloma Virus 56
4.9 Vaccines for COVID-19 57
4.10 Vaccines for Other Diseases 60
5 Segmentation of North America Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67
6 Segmentation of North America Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72
7 North America Market 2020-2026 by Country 74
7.1 Overview of North America Market 74
7.2 U.S. 77
7.3 Canada 82
7.4 Mexico 85
8 Competitive Landscape 88
8.1 Overview of Key Vendors 88
8.2 New Product Launch, Partnership, Investment, and M&A 91
8.3 Company Profiles 92
AstraZeneca plc 92
Bavarian Nordic A/S 95
China National Biotec Group Company Ltd. 98
CSL Ltd. 100
Daiichi Sankyo Co. Ltd 102
Emergent BioSolutions Inc. 104
GlaxoSmithKline plc 106
Johnson & Johnson 110
Merck & Co. 112
Moderna Inc. 114
Novavax, Inc. 115
Pfizer Inc. 117
Sanofi SA 121
Takeda Pharmaceutical Co. Ltd. 123
9 Investing in North America Market: Risk Assessment and Management 125
9.1 Risk Evaluation of North America Market 125
9.2 Critical Success Factors (CSFs) 128
Related Reports and Products 131Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2020-2026 17
ALSO READ : http://www.marketwatch.com/story/global-bottom-roll-away-tool-chest...
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market 31
Table 4. North America Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 39
Table 5. North America Preventive Vaccines Market by Disease, 2016-2026, $ mn 48
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 58
Table 7. North America Preventive Vaccines Market by Administration, 2016-2026, $ mn 61
Table 8. North America Preventive Vaccines Market by Patient, 2016-2026, $ mn 68
Table 9. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 71
Table 10. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 73
Table 11. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 75
Table 12. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 79
Table 13. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 79
Table 14. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 80
Table 15. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 83
Table 16. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 83
Table 17. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 84
Table 18. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 86
Table 19. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 86
Table 20. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 87
Table 21. AstraZeneca plc: Company Snapshot 92
Table 22. AstraZeneca plc: Revenue, 2018-2020, $ bn 93
Table 23. Bavarian Nordic A/S: Company Snapshot 95
Table 24. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 96
Table 25. China National Biotec Group Company Ltd.: Company Snapshot 98
Table 26. CSL Ltd.: Company Snapshot 100
Table 27. Daiichi Sankyo Co. Ltd.: Company Snapshot 102
Table 28. Emergent BioSolutions Inc.: Company Snapshot 104
Table 29. GlaxoSmithKline: Company Snapshot 106
Table 30. GlaxoSmithKline: Business Segmentation 107
Table 31. GlaxoSmithKline: Product Portfolio 108
Table 32. GlaxoSmithKline: Revenue, 2018-2020, $ bn 109
Table 33. GlaxoSmithKline: Recent Developments 109
Table 34. Johnson & Johnson: Company Snapshot 110
Table 35. Johnson & Johnson: Business Segments 111
Table 36. Merck & Co., Inc.: Company Snapshot 112
Table 37. Merck & Co., Inc.: Business Segmentation 112
Table 38. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 113
Table 39. Moderna Inc.: Company Snapshot 114
Table 40. Novavax, Inc.: Company Snapshot 115
Table 41. Pfizer Inc.: Company Snapshot 117
Table 42. Pfizer Inc.: Business Segmentation 118
Table 43. Pfizer Inc.: Product Portfolio 119
Table 44. Pfizer Inc.: Revenue, 2018-2020, $ bn 120
Table 45. Pfizer Inc.: Recent Developments 120
Table 46. Sanofi: Company Snapshot 121
Table 47. Sanofi: Business Segmentation 121
Table 48. Sanofi: Revenue, 2018-2020, $ bn 122
Table 49. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 123
Table 50. Risk Evaluation for Investing in North America Market, 2020-2026 126
Table 51. Critical Success Factors and Key Takeaways 129Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026 16
Figure 4. North America Preventive Vaccines Market, 2016-2026, $ mn 19
Figure 5. Development Stages of Preventive Vaccines 20
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of North America Preventive Vaccines Market 25
Figure 8. Primary Restraints and Impact Factors of North America Preventive Vaccines Market 28
Figure 9. Investment Opportunity Analysis 32
Figure 10. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market 35
Figure 11. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue 40
Figure 12. Contribution to North America 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 40
Figure 13. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 41
Figure 14. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 42
Figure 15. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 43
Figure 16. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 44
Figure 17. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 45
Figure 18. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 46
Figure 19. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 47
Figure 20. Breakdown of North America Preventive Vaccines Market by Disease, 2020-2026, % of Revenue 49
Figure 21. Contribution to North America 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 49
Figure 22. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 50
Figure 23. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 51
Figure 24. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 52
Figure 25. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 53
Figure 26. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 54
Figure 27. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 55
Figure 28. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 56
Figure 29. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 57
Figure 30. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 60
Figure 31. Breakdown of North America Preventive Vaccines Market by Administration, 2020-2
....contiued

CONTACT DETAILS
[email protected]
+44 203 500 2763
+1 62 825 80070
971 0503084105